An in situ Opioid Drug Deactivation Kit for Home Use

家用阿片类药物原位灭活套件

• 批准号: 8751075
• 负责人: SHANTHASHANTHA SARANGAPANI
• 金额: $ 14.98万
• 依托单位: INNOVATIVE CHEMICAL/ENVIRONMENTAL TECH
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-20 至 2014-03-19
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8751075
• 关键词: Chemicals; Codeine; Contractor; Coupled; Data; Environmental Impact; Fentanyl; Home environment; In Situ; Monitor; Morphine; Opioid; Oxycodone; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Reaction; Recovery; Research Project Grants; Risk Assessment; Salts; Small Business Innovation Research Grant; Testing; base; success; usability

Objective 1: In this objective, the Contractor shall obtain the pure and pharmaceutical forms of codeine, morphine, oxycodone and fentanyl from DEA-certified commercial distributor(s) as well as other materials required for testing of the kit. The Contractor shall also identify parameters for the degradation of the pure and pharmaceutical forms of these drugs. Objective 2: In this objective, the Contractor shall construct a preliminary kit and monitor the progress of the reaction with the use of the pure opioid salts and actual medications. Objective 3: In this objective, the Contractor shall analyze all data and provide conclusions on the rate of disappearance of the active opioids concentration. The Contractor shall conduct additional risk assessment and product usability testing contingent upon the success of Objectives 1 and 2.

目标 1：在此目标中，承包商应从 DEA 认证的商业经销商处获取纯药形式的可待因、吗啡、羟考酮和芬太尼，以及测试试剂盒所需的其他材料。承包商还应确定这些药物的纯品和药物形式的降解参数。 目标 2：在此目标中，承包商应构建初步试剂盒并监测使用纯阿片盐和实际药物的反应进度。 目标 3：在此目标中，承包商应分析所有数据并提供有关活性阿片类药物浓度消失率的结论。承包商应根据目标 1 和 2 的成功情况进行额外的风险评估和产品可用性测试。